Stock Price, News, Quote and Profile of CARTESIAN THERAPEUTICS INC(NASDAQ:RNAC) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CARTESIAN THERAPEUTICS INC

NASDAQ:RNAC (5/20/2024, 7:00:02 PM)

After market: 25.83 0 (0%)

25.83

-0.6 (-2.27%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap459.77M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG.

Company Info

CARTESIAN THERAPEUTICS INC

65 Grove Street

Watertown MASSACHUSETTS

P: 16179231400

Employees: 58

Website: https://selectabio.com/

RNAC News

8 days ago - Cartesian Therapeutics, Inc.Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company...

13 days ago - InvestorPlaceRNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024

RNAC stock results show that Cartesian Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

13 days ago - BusinessInsiderRNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cartesian Therapeutics (NASDAQ:RNAC) just reported results for the first quarte...

13 days ago - Cartesian Therapeutics, Inc.Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for...